Biomedical Research Networking Centre Consortium of Oncology Instituto de Salud Carlos 3 28029 Madrid Spain

CLIP Department of Pediatric Hematology and Oncology 2nd Medical Faculty Charles University and University Hospital Motol Prague Czech Republic

Department of Diagnostic Sciences Faculty of Medicine and Health Sciences Ghent University Ghent Belgium

Department of Hematology Complejo Asistencial de Ávila Ávila Spain

Department of Hematology Complejo Asistencial de Zamora Zamora Spain

Department of Hematology Complejo Asistencial Universitario de León León Spain

Department of Hematology Complejo Asistencial Universitario de Palencia Palencia Spain

Department of Hematology Hospital Clínico Universitario de Valladolid Valladolid Spain

Department of Hematology Hospital Universitario de Burgos Burgos Spain

Department of Immunology Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands

Department of Immunology Leiden University Medical Center Leiden The Netherlands

Dutch Childhood Oncology Group The Hague The Netherlands

FACS Stem Cell Laboratory Kantonsspital Aarau Aarau Switzerland

Hematology Department and Laboratory Medicine Department Hospital Universitario Central de Asturias Oviedo Spain

Hematology Department University Hospital of Salamanca CIBERONC Salamanca Spain

Hematology Service Hospital Clinic Barcelona Spain

Hematology Service University Hospital of Getafe Madrid Spain

Pathology Service Hospital del Mar Barcelona Spain

Translational and Clinical Research Program Centro de Investigación del Cáncer Salamanca Spain

Zobrazit více v PubMed

Falini B, Martelli MP, Pileri SA, Mecucci C. Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help. Haematologica. 2010;95:529–34. doi: 10.3324/haematol.2009.017822. PubMed DOI PMC

Falini B, Martelli MP, Bolli N, Bonasso R, Ghia E, Pallotta MT, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood. 2006;108:1999–2005. doi: 10.1182/blood-2006-03-007013. PubMed DOI

Park BG, Chi H-S, Jang S, Park C-J, Kim D-Y, Lee J-H, et al. Association of cup-like nuclei in blasts with FLT3 and NPM1 mutations in acute myeloid leukemia. Ann Hematol. 2013;92:451–7. doi: 10.1007/s00277-012-1645-5. PubMed DOI

Mason EF, Hasserjian RP, Aggarwal N, Seegmiller AC, Pozdnyakova O. Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome. Blood Adv. 2019;3:3322–32. doi: 10.1182/bloodadvances.2019000328. PubMed DOI PMC

Woolthuis CM, Mulder AB, Verkaik-Schakel RN, Rosati S, Diepstra A, van den Berg E, et al. A single center analysis of nucleophosmin in acute myeloid leukemia: value of combining immunohistochemistry with molecular mutation analysis. Haematologica. 2013;98:1532–8. doi: 10.3324/haematol.2012.079806. PubMed DOI PMC

Angelini DF, Ottone T, Guerrera G, Lavorgna S, Cittadini M, Buccisano F, et al. A leukemia-associated CD34/CD123/CD25/CD99+ immunophenotype identifies FLT3-mutated clones in acute myeloid leukemia. Clin Cancer Res. 2015;21:3977–85. doi: 10.1158/1078-0432.CCR-14-3186. PubMed DOI

Mer AS, Heath EM, Madani Tonekaboni SA, Dogan-Artun N, Nair SK, Murison A, et al. Biological and therapeutic implications of a unique subtype of NPM1 mutated AML. Nat Commun. 2021;12:1054. doi: 10.1038/s41467-021-21233-0. PubMed DOI PMC

Martelli MP, Pettirossi V, Thiede C, Bonifacio E, Mezzasoma F, Cecchini D, et al. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood. 2010;116:3907–22. doi: 10.1182/blood-2009-08-238899. PubMed DOI

Pianigiani G, Rocchio F, Peruzzi S, Andresen V, Bigerna B, Sorcini D, et al. The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein. Leukemia. 2022;36:1931–4. 10.1038/s41375-022-01593-2. PubMed PMC

Brunetti L, Gundry MC, Sorcini D, Guzman AG, Huang Y-H, Ramabadran R, et al. Mutant NPM1 maintains the leukemic state through HOX expression. Cancer Cell. 2018;34:499–512.e9. doi: 10.1016/j.ccell.2018.08.005. PubMed DOI PMC

Matarraz S, Almeida J, Flores-Montero J, Lécrevisse Q, Guerri V, López A, et al. Introduction to the diagnosis and classification of monocytic-lineage leukemias by flow. Cytom B Clin Cytom. 2017;92:218–27. doi: 10.1002/cyto.b.21219. PubMed DOI

Wang AJ, Han Y, Jia N, Chen P, Minden MD. NPM1c impedes CTCF functions through cytoplasmic mislocalization in acute myeloid leukemia. Leukemia. 2020;34:1278–90. doi: 10.1038/s41375-019-0681-8. PubMed DOI

Gu X, Ebrahem Q, Mahfouz RZ, Hasipek M, Enane F, Radivoyevitch T, et al. Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J Clin Invest. 2018; 128:4260–79. PubMed PMC

Dawson MA, Gudgin EJ, Horton SJ, Giotopoulos G, Meduri E, Robson S, et al. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Leukemia. 2014;28:311–20. doi: 10.1038/leu.2013.338. PubMed DOI PMC

Abdellateif MS, Kassem AB, El-Meligui YM. Combined expression of CD34 and FLT3-internal tandem duplication mutation predicts poor response to treatment in acute myeloid leukemia. Int J Gen Med. 2020;13:867–79. doi: 10.2147/IJGM.S276138. PubMed DOI PMC